XBIO
What one share of Xenetic Biosciences holds
Pharmaceutical Preparations
We are a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers. Our proprietary DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (“NETs”), which are involved in cancer growth, metastasis and progression, and contribute to immunotherapy, chemotherapy and radiotherapy resistance.
Xenetic Biosciences’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $1.57 |
|---|---|
| Profit | −$1.19 |
| Cash and investments | $2.76 |
| Book value | $2.59 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2016 | — | −$78.38 | $0.02 | −$11.85 | — | $35.26 |
| 2017 | — | −$4.15 | $0.01 | $1.71 | — | $16.41 |
| 2018 | — | −$96.56 | $0.00 | −$85.50 | — | $126.46 |
| 2019 | $0.06 | −$63.31 | — | −$22.43 | — | — |
| 2020 | $0.68 | −$17.04 | — | −$6.68 | — | $13.97 |
| 2021 | $1.13 | −$5.49 | — | −$4.61 | — | $13.69 |
| 2022 | $1.20 | −$4.61 | — | −$3.27 | — | $9.00 |
| 2023 | $1.66 | −$2.71 | — | −$2.69 | — | $6.36 |
| 2024 | $1.62 | −$2.57 | — | −$1.83 | — | $3.90 |
| 2025 | $1.75 | −$1.58 | — | −$1.34 | — | $3.23 |